These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
709 related articles for article (PubMed ID: 34923955)
1. Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma. Deng M; Lin JB; Zhao RC; Li SH; Lin WP; Zou JW; Wei W; Guo RP BMC Cancer; 2021 Dec; 21(1):1347. PubMed ID: 34923955 [TBL] [Abstract][Full Text] [Related]
2. Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune-related lncRNA. Shen S; Chen X; Hu X; Huo J; Luo L; Zhou X Cancer Med; 2021 Sep; 10(18):6561-6575. PubMed ID: 34378851 [TBL] [Abstract][Full Text] [Related]
3. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5. Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092 [TBL] [Abstract][Full Text] [Related]
4. Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma. Sun JX; Xia QD; Liu CQ; Xu JZ; Xun Y; Lu JL; Hu J; Wang SG Dis Markers; 2021; 2021():8800358. PubMed ID: 34512816 [TBL] [Abstract][Full Text] [Related]
5. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment. Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776 [TBL] [Abstract][Full Text] [Related]
6. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data. Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866 [TBL] [Abstract][Full Text] [Related]
7. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma. Wang S; Bai H; Fei S; Miao B Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914 [TBL] [Abstract][Full Text] [Related]
8. Identification of Immune-Related lncRNA Pairs and Construction and Validation of a New Prognostic Signature of Colon Cancer. Xu M; Li Q; Zhang J; Xie H Can J Gastroenterol Hepatol; 2022; 2022():5827544. PubMed ID: 35399646 [TBL] [Abstract][Full Text] [Related]
9. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma. Yan J; Zhou C; Guo K; Li Q; Wang Z J Cell Biochem; 2019 Jan; 120(1):213-223. PubMed ID: 30206981 [TBL] [Abstract][Full Text] [Related]
10. Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma. Tu K; Li J; Mo H; Xian Y; Xu Q; Xiao X Int J Med Sci; 2021; 18(9):2030-2041. PubMed ID: 33850474 [TBL] [Abstract][Full Text] [Related]
11. Construction of a new immune-related lncRNA model and prediction of treatment and survival prognosis of human colon cancer. Liu S; Peng X; Wu X; Bu F; Yu Z; Zhu J; Luo C; Zhang W; Liu J; Huang J World J Surg Oncol; 2022 Mar; 20(1):71. PubMed ID: 35249533 [TBL] [Abstract][Full Text] [Related]
12. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma. Dai Y; Qiang W; Lin K; Gui Y; Lan X; Wang D Cancer Immunol Immunother; 2021 Apr; 70(4):967-979. PubMed ID: 33089373 [TBL] [Abstract][Full Text] [Related]
13. Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma. Hong W; Liang L; Gu Y; Qi Z; Qiu H; Yang X; Zeng W; Ma L; Xie J Mol Ther Nucleic Acids; 2020 Dec; 22():937-947. PubMed ID: 33251044 [TBL] [Abstract][Full Text] [Related]
14. A Novel Ferroptosis-Related Long Non-Coding RNA Prognostic Signature Correlates With Genomic Heterogeneity, Immunosuppressive Phenotype, and Drug Sensitivity in Hepatocellular Carcinoma. Li G; Liu Y; Zhang Y; Xu Y; Zhang J; Wei X; Zhang Z; Zhang C; Feng J; Li Q; Wang G Front Immunol; 2022; 13():929089. PubMed ID: 35874689 [TBL] [Abstract][Full Text] [Related]
15. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma. Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911 [TBL] [Abstract][Full Text] [Related]
16. Identification of a five-immune gene model as an independent prognostic factor in hepatocellular carcinoma. Chen H; Li Y; Xiao SY; Guo J BMC Cancer; 2021 Mar; 21(1):278. PubMed ID: 33726698 [TBL] [Abstract][Full Text] [Related]
17. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature. Zhao K; Xu L; Li F; Ao J; Jiang G; Shi R; Chen F; Luo Q Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32789471 [TBL] [Abstract][Full Text] [Related]
18. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma. Xu Q; Wang Y; Huang W Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322 [TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma. Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566 [TBL] [Abstract][Full Text] [Related]
20. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. Li L; Xie R; Lu G Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]